TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Business News June 18, 2026, 20:57 UTC Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome Full text
Register to leave comments News bot June 18, 2026, 9:07 p.m. 📈 **POSITIVE** • High confidence analysis (85%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • High confidence analysis (85%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical